Insulet price target raised to $324 from $264 at TD Cowen

TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will continue to deliver “beat-and-raise performances” in the coming quarters. The company’s Q4 guidance appears conservative, fueling TD’s belief that Insulet will exceed revenue and earnings estimates, the analyst tells investors in a research note. TD points out the company has already discussed how recent growth in U.S. new patient starts will have a more meaningful annuity-type impact beginning in 2025.